$-0.26 EPS Expected for Fate Therapeutics, Inc. (FATE)

July 14, 2018 - By Pearl Odom

Investors sentiment increased to 2.08 in 2018 Q1. Its up 0.50, from 1.58 in 2017Q4. It increased, as 9 investors sold Fate Therapeutics, Inc. shares while 17 reduced holdings. 23 funds opened positions while 31 raised stakes. 36.46 million shares or 12.96% more from 32.27 million shares in 2017Q4 were reported.
Amer Intll Group Incorporated holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 30,864 shares. Nuveen Asset Mngmt Limited holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 54,063 shares. Metropolitan Life Ins New York has 15,799 shares for 0% of their portfolio. Parametric Port Limited Company invested 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Renaissance Technology Ltd Liability Com owns 40,100 shares. Wells Fargo And Mn owns 104,647 shares. Quantbot Technology L P invested in 0.01% or 10,984 shares. State Of Wisconsin Inv Board has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 30,000 shares. 88,364 are held by Ameriprise Finance. Citigroup owns 10,298 shares. Voya Inv Mgmt Limited Liability Corp stated it has 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Neuberger Berman Gru Ltd Liability has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Strs Ohio has 11,100 shares for 0% of their portfolio. Virtu Limited Liability Corporation holds 16,521 shares. Bridgeway Cap Inc invested in 202,000 shares.

Analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to report $-0.26 EPS on August, 13.They anticipate $0.03 EPS change or 13.04 % from last quarter’s $-0.23 EPS. After having $-0.27 EPS previously, Fate Therapeutics, Inc.’s analysts see -3.70 % EPS growth. The stock decreased 0.50% or $0.06 during the last trading session, reaching $11.86. About 95,260 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 233.04% since July 14, 2017 and is uptrending. It has outperformed by 220.47% the S&P500.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Fate Therapeutics had 10 analyst reports since March 6, 2018 according to SRatingsIntel. On Thursday, March 29 the stock rating was maintained by H.C. Wainwright with “Hold”. The rating was maintained by Wells Fargo on Friday, April 6 with “Buy”. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Hold” rating by Raymond James on Tuesday, March 6. The firm has “Buy” rating given on Thursday, March 15 by Piper Jaffray. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Outperform” rating given on Tuesday, March 6 by Wedbush. The firm has “Outperform” rating by BMO Capital Markets given on Tuesday, March 6. H.C. Wainwright downgraded the shares of FATE in report on Tuesday, March 6 to “Neutral” rating. The firm has “Buy” rating by Piper Jaffray given on Wednesday, May 16. H.C. Wainwright maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Tuesday, March 20 with “Hold” rating. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Buy” rating by Piper Jaffray on Tuesday, March 6.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $626.90 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

More news for Fate Therapeutics, Inc. (NASDAQ:FATE) were recently published by: Prnewswire.com, which released: “Stem Cell Companies Innovating for the Future” on July 12, 2018. Businesswire.com‘s article titled: “Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance” and published on June 20, 2018 is yet another important article.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.